Formulation And Evaluation of Lipo-Nanosphere Loaded Docetaxel Drug
Anticancer drugs
Docetaxel
Lipo-Nanospheres
Triglycerides
As nanotechnology advances, the nanoliposphere is being considered as a possible drug carrier to enhance the bioavailability of some lipophilic drugs. Lipospheres are often employed to deliver hydrophobic agents because lipids can make pharmaceuticals more soluble and release them in a controlled manner. Antineoplastic medication docetaxel (DCX) is useful for treating a variety of complicated malignancies, particularly cancers of the breast and ovary. Because it is highly hydrophobic, low bioavailability due to the extreme toxicity of DCX, it was only developed for intravenous infusion on the market at a dose of 100 mg/m every three weeks (Taxotere®). The creation of lipo-nanospheres (LPNS) as docetaxel carriers is discussed in this work. The synthesized lipo-nanospheres, which are made of biodegradable and bio-acceptable lipids, are described for surface morphology, crystallinity, and release studies. This accomplished by Fourier transform infrared spectroscopy (FTIR), polydispersity index, particle size, and in vitro release studies
Due to delayed drug diffusion from lipo-nanospheres, docetaxel's in vitro release behaviors from the created lipo-nanospheres showed a biphasic pattern, with a quick initial release and a slower, continuous release over the course of 24 hours. Our findings show that the created formulation of lipo-nanospheres containing docetaxel can be effective against complicated malignancies.